Impact of serum Wisteria floribunda agglutinin positive Mac-2-binding protein and serum interferon-γ-inducible protein-10 in primary biliary cirrhosis

Hepatology Research

Volumn 46, Issue 6, 2016, Pages 575-583

  Nishikawa, Hiroki ^a   Enomoto, Hirayuki ^a   Iwata, Yoshinori ^a   Hasegawa, Kunihiro ^a   Nakano, Chikage ^a   Takata, Ryo ^a   Nishimura, Takashi ^a   Yoh, Kazunori ^a   Aizawa, Nobuhiro ^a   Sakai, Yoshiyuki ^a   Ikeda, Naoto ^a   Takashima, Tomoyuki ^a   Ishii, Akio ^a   Iijima, Hiroko ^a   Nishiguchi, Shuhei ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Inflammation activity; Interferon inducible protein 10; Liver fibrosis; Primary biliary cirrhosis; Wisteria floribunda agglutinin positive Mac 2 binding protein

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BINDING PROTEIN; C REACTIVE PROTEIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; UNCLASSIFIED DRUG; WISTERIA FLORIBUNDA AGGLUTININ MAC 2 BINDING PROTEIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

EID: 84949035389     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12595     Document Type: Article

References (35)

1. Kaplan MM. Primary biliary cirrhosis. N Engl J Med 1996; 335: 1570-80.
2. Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ, American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50: 291-308.
3. Ghonem NS, Assis DN, Boyer JL. On fibrates and cholestasis: A review. Hepatology 2015 Feb 11 [Epub ahead of print].
4. Iwasaki S, Ohira H, Nishiguchi S et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008; 38 (6): 557-64.
5. Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for Therapy of Autoimmune Liver Disease. Semin Liver Dis 2007; 27 (2): 214-26.
6. Cavazza A, Caballerí L, Floreani A et al. Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: comparative analysis from two centers. Hepatology 2009; 50 (4): 1162-8.
7. Piscaglia F, Sagrini E. Malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 2008; 20: 1-4.
8. Tsochatzis EA, Crossan C, Longworth L et al. Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis C. Hepatology 2014; 60 (3): 832-43.
9. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142 (6): 1293-302.
10. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014; 60 (5): 1563-70.
11. Fujiyoshi M, Kuno A, Gotoh M et al. Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma. J Gastroenterol 2015 Mar 15 [Epub ahead of print].
12. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J Gastroenterol 2015; 50 (1): 76-84.
13. Tamaki N, Kurosaki M, Kuno A et al. Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. Hepatol Res 2015; Jan 6 [Epub ahead of print].
14. Hanai T, Shiraki M, Ohnishi S et al. Impact of serum glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis. Hepatol Res 2015 Jan 6 [Epub ahead of print].
15. Toyoda H, Kumada T, Tada T et al. Serum WFA+-M2BP Levels as a Prognostic Factor in Patients with Early Hepatocellular Carcinoma Undergoing Curative Resection. Liver Int 2015 Jul 2 [Epub ahead of print].
16. Grebely J, Feld JJ, Applegate T et al. Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology 2013; 57 (6): 2124-34.
17. Diago M, Castellano G, García-Samaniego J et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut 2006; 55 (3): 374-9.
18. Lagging M, Romero AI, Westin J et al. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection. Hepatology 2006; 44 (6): 1617-25.
19. Nishikawa H, Enomoto H, Nasu A et al. Clinical significance of pretreatment serum interferon-gamma-inducible protein 10 concentrations in chronic hepatitis C patients treated with telaprevir-based triple therapy. Hepatol Res 2014; 44 (14): E397-407.
20. Zeremski M, Petrovic LM, Chiriboga L et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008; 48: 1440-50.
21. Nishioji K, Okanoue T, Itoh Y et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123 (2): 271-9.
22. Umemura T, Joshita S, Sekiguchi T et al. Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. Am J Gastroenterol 2015; 110 (6): 857-64.
23. Kuiper EM, Zondervan PE, van Buuren HR. Paris criteria are effective in diagnosis of primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. Clin Gastroenterol Hepatol 2010; 8 (6): 530-4.
24. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38 (2): 518-26.
25. Sterling RK, Lissen E, Clumeck N et al. APRICOT Clinical Investigators: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43 (6): 1317-25.
26. Kuno A, Ikehara Y, Tanaka Y et al. A serum "sweet-doughnut" 272 protein facilitates fibrosis evaluation and therapy assessment in patients 273 with viral hepatitis. Sci Rep 2013; 3: 1065.
27. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profiling. Proteomics Clin Appl 2013; 7 (9-10): 642-7.
28. Iwata K, Enomoto H, Nishiguchi S et al. Serum zinc value in patients with hepatitis virus-related chronic liver disease: association with the histological degree of liver fibrosis and with the severity of varices in compensated cirrhosis. J Clin Biochem Nutr 2014; 55 (2): 147-52.
29. Fernandez M, Trépo E, Degré D et al. Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease. Eur J Gastroenterol Hepatol 2015 May 18 [Epub ahead of print].
30. Ma LN, Liu XY, Luo X et al. Serum high-sensitivity C-reactive protein are associated with HBV replication, liver damage and fibrosis in patients with chronic hepatitis B. Hepatogastroenterology 2015; 62 (138): 368-72.
31. Fujiwara N, Tateishi R, Nakagawa H et al. Slight elevation of high-sensitivity C-reactive protein to predict recurrence and survival in patients with early stage hepatitis C-related hepatocellular carcinoma. Hepatol Res 2015; 45 (6): 645-55.
32. Yoneda M, Mawatari H, Fujita K et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007; 42 (7): 573-82.
33. Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol 2014 Oct 18 [Epub ahead of print].
34. Askarieh G, Alsiö A, Pugnale P et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology 2010; 51: 1523-30.
35. Rostami S, Parsian H. Hyaluronic Acid: from biochemical characteristics to its clinical translation in assessment of liver fibrosis. Hepat Mon 2013; 13 (12): e13787.